He from the sales of the sales that





FIG. 1A

2 / 21



W

1313

ļ.£

FIG. 1B




FIG. 1D

Title: TRANSGENIC MOUSE FOR TARGETED RECOMBINATI MEDIATED BY MODIFIED CR Inventor(s): Pierre Chambon et al. DOCKET NO.: 065691/0222




FIG. 2A

þ.

Title: TRANSGENIC MOUSE FOR TARGETED RECOMBINATI MEDIATED BY MODIFIED CR Inventor(s): Pierre Chambon et al.

DOCKET NO.: 065691/0222




FIG. 2B

And the first that the little with

Ų

The flow of the sale sale sale

TARGETED RECOMBINATION
MEDIATED BY MODIFIED CRE
Inventor(s): Pierre Chambon et al.

DOCKET NO.: 065691/0222





FIG. 3.

Į,






FIG. 48

IJ

<u>|</u>

1

Inventor(s): Pierre Chambon et a DOCKET NO.: 065691/0222


7 / 21.

## Tam + L2 allele (12,5 kb) L-allele (3,8 kb)

FIG. 5

DOCKET NO.: 065691/0222

8 / 21



Part Hall the man from the first that

ij




FIG. 6A

FIG. 6B




FIG. 6C

DOCKET NO.: 065691/0222

9 / 21




FIG. 6D

Total man of




FIG. 6E




FIG. 6F

The state of the s

Title: TRANSGENIC MOUSE FOR TARGETED RECOMBINATION MEDIATED BY MODIFIED CRE-ER

Inventor(s): Pierre Chambon et al. DOCKET NO.: 065691/0222

10 / 21

## α-AT-Cre-ERT(tg/0)/RXRαL2/L2

Heart	Liver
Jour 0	0
1 2	L- allele (8,5 kb)

FIG. 7

half the first state that the same result that

ij DOCKET NO.: 065691/0222




FIG. 8

 Title: TRANSGENIC MOUSE FOR TARGETED RECOMBINATION MEDIATED BY MODIFIED CRIMINATION Inventor(s): Pierre Chambon et al. DOCKET NO.: 065691/0222







FIG. 9

Title: TRANSGENIC MOUSE FOR TARGETED RECOMBINATION MEDIATED BY MODIFIED CRE-I

Inventor(s): Pierre Chambon et al. DOCKET NO.: 065691/0222

13 / 21



K5-Cre-ER<sup>T2</sup>

K5-Cre-ER<sup>T3</sup>


FIG. 10

The time that the true that the time that the

# #3 FF

The last office office.

Title: TRANSGENIC MOUSE FOR TARGETED RECOMBINATION OF TARGETED BY MODIFIED -ER Inventor(s): Pierre Chambon et al. DOCKET NO.: 065691/0222




LA Comment of the last that

THE THE BUTTON

1.7

DOCKET NO.: 065691/0222






FIG. 12A-B

Ļij

DOCKET NO.: 065691/0222




FIG. 12C-D

The first first from the first first first first first

C.

14 1.1 DOCKET NO.: 065691/0222




FIG. 13A-B

Title: TRANSGENIC MOUSE FOR
TABLETED RECOMBINATION
MED ED BY MODIFIED CRE-ER
Inventor(s): Pierre Chambon et al.
DOCKET NO.: 065691/0222

18 / 21

nick) of blopsies of &-16 mm tuniors from CT and RXR $lpha$ ep-/- mice, 25 and 30 weeks after the start	
n Se,	
RXR @P-/- n	
and	
5	
fren	
UMOR	
mm t	3
7-16-1	
9	
plopste	
Ç o	
n-thick) of	
iπ S)	
sections	
raffin	<b>=</b>
of pa	Jewer.
yala	
	֡֝֝֝֝֝֡֝֝֡֝֝֡֝
gical	2
istolo	901
<b>=</b> 7	3

ļ.

	After DMBA/TPA Nu	After DMBA/TPA Number of papillomas		Pap	Papillomas exhibiting	Ting		•		
	-		In situ carcinoma	FC	SCC (I)	(II) 22S	SCC(III)	SCC (IV)	spcc	ВСС
<u> </u>	<b>14</b> francis and gar and gar and gar and gar									
10	- - - -	 & 5	1/20 (5%) 0/20 1/31 (~3%) 5/31 (~16%)	0/20 5/31 (~16%)	0/20 0/31	0/20	0/20	0/20	0/20	0/20
IIXRa 8P-1-	245	<b>.</b>	2/20 (10%)	8/20 (40%)	0/20	0/20	0/20	0/20	0/20	0/20
	98	35	1/35(-3%)	7/35 (20%)	3/35 (~6%)	3/32 (~8%)		1/35 (~3%) 2/35(~6%) 2/35(~6%) 3/35(~9%)	2/35(-6%)	3/35(~9%)

FC, focal caruligma; SCC, squainous cell carcinoma; SpCC, spindle cell carcinoma; BCC, basal cell carcinoma

FIG. 13

THE

# ## ## # ## ##





FIG. 14A-B

# ## ## # ## # DOCKET NO.: 065691/0222



**FIG. 14C** 

to the to the the to the

Ļ

## ## ## ##

DOCKET NO.: 065691/0222




FIG. 15